Comparison of Cognitive Rehabilitation versus Donepezil Therapy on Memory Performance, Attention, Quality of Life, and Depression among Multiple Sclerosis Patients
Joint Authors
Shahpouri, Mohammad Mahdi
Barekatain, Majid
Tavakoli, Mahgol
Mirmosayyeb, Omid
Safaei, Ali
Shaygannejad, Vahid
Source
Neurology Research International
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-11-23
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Background.
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that affects cognitive performance and leads to depression and decreased quality of life (QOL).
The current study aims to assess the effects of cognitive rehabilitation versus donepezil therapy on memory, attention, depression, and QOL in MS patients compared to placebo and control groups.
Methods.
Eighty MS patients were randomly selected from parallel randomized trials and divided into four groups: A: cognitive rehabilitation (10 sessions of 120 minutes), B: control (no intervention), C: donepezil (10 mg daily), and D: placebo.
Patients received the intervention for three months.
They were assessed for cognitive status, depression, and QOL prior to the intervention and immediately after that using abbreviated mental test (AMT), prospective and retrospective memory questionnaire (PRMQ), everyday memory questionnaire (EMQ), digit span, MSQOL-54, and second edition Beck depression inventory (BDI).
We compared scores between groups after the intervention, as well as the progression of scores in every single group.
Results.
The cognitive rehabilitation group showed improvement in EMQ, RPMQ, digit span, physical and mental health subscales of MSQOL54, and depression P<0.05.
We observed the same effect for donepezil except for the digit span test P=0.15.
Intergroup comparison of scores showed the superiority of cognitive rehabilitation over donepezil in digit span, depression, and mental health scores.
Conclusion.
Both donepezil and cognitive rehabilitation effectively improve memory performance, attention, depression, and QOL in MS patients.
Cognitive rehabilitation is superior altogether.
This study is registered with the Iranian registry of clinical trials http://clinicaltrials.gov/ct2/show/IRCT2016042227522N1.
American Psychological Association (APA)
Shahpouri, Mohammad Mahdi& Barekatain, Majid& Tavakoli, Mahgol& Mirmosayyeb, Omid& Safaei, Ali& Shaygannejad, Vahid. 2020. Comparison of Cognitive Rehabilitation versus Donepezil Therapy on Memory Performance, Attention, Quality of Life, and Depression among Multiple Sclerosis Patients. Neurology Research International،Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1203244
Modern Language Association (MLA)
Shahpouri, Mohammad Mahdi…[et al.]. Comparison of Cognitive Rehabilitation versus Donepezil Therapy on Memory Performance, Attention, Quality of Life, and Depression among Multiple Sclerosis Patients. Neurology Research International No. 2020 (2020), pp.1-8.
https://search.emarefa.net/detail/BIM-1203244
American Medical Association (AMA)
Shahpouri, Mohammad Mahdi& Barekatain, Majid& Tavakoli, Mahgol& Mirmosayyeb, Omid& Safaei, Ali& Shaygannejad, Vahid. Comparison of Cognitive Rehabilitation versus Donepezil Therapy on Memory Performance, Attention, Quality of Life, and Depression among Multiple Sclerosis Patients. Neurology Research International. 2020. Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1203244
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1203244